CASE STUDIES

The smartest (and easiest) way to identify ideal partners and plan strategic outreach.

"We recently used MotionHall to generate target lists of potential licensees for two indications: one where we’ve been working for several years, and a second that represents a new disease area for business development activities. The lists are amazingly accurate, and in the case of the new indication has saved us a great deal of time and effort in trying to generate the same list using traditional methodologies.”

PAUL BRENNAN,

VP BUSINESS DEVELOPMENT, AQUINOX PHARMACEUTICALS


The Deal

Phase 3 Pain Seeking M&A

The Dealmaker

Investment bank active in life sciences bd&l.

Value Added

OutMatch AI saw past competitive concerns and accurately predicted the final buyer. Identified a #2 match from top pharma the bankers hadn't considered. Discovered an additional 44 match possibilities to ensure getting a deal done.


The Deal

Phase 2 Cardio Metabolic Seeking US Global Partnership

Value Added

OutMatch AI predicted 100% of matches that would advance to data-room conversations and discovered a total of 91 match possibilities to improve optionality and drive competition for the deal.

 

The Dealmaker

Investment bank active in life sciences bd&l.


The Deal

Phase 3 Allergy Seeking Ex-US Regional Partnerships

 

The Dealmaker

Senior BD&L executive at a publicly traded clinical stage company.

 

Value Added

Identified strategically ideal and interested partner prospects amongst medium and specialty pharma in Europe and Asia-Pacific. Discovered a total of 38 match possibilities for a difficult asset class.

 


The Deal

Pre-Clinical Dermatology Seeking Global Partnership

The Dealmaker

Senior BD&L consultant with extensive history in top pharma.

Value Added

Identified 71 match possibilities over and above the 8 the consultant had in mind. Identified a #1 and #3 match the consultant hadn't considered. 


The Deal

Phase 2 Dermatology Seeking M&A

The Dealmaker

Investment bank active in life sciences bd&l.

Value Added

Extended the bank's internal list by 25 companies, for a total of 53 partnering targets. Identified 6 top matches the bank had not considered or was unfamiliar with.


The Deal

Phase 3 Pain Seeking Ex-US Partnership

The Dealmaker

Senior BD&L executive at a publicly traded clinical stage company.

Value Added

Identified 50 matches across top, medium and specialty pharma active in the European and APAC region with appropriate dedication to the therapeutic area and an appropriate salesforce in place.


Want to take OutMatch for a spin? Sign up for free, and receive an interactive sample featuring a non-confidential model of Jounce's JTX-2011.


In god we trust, all others must bring data.
— Anand Sanwal, CEO of CBInsights